DoW Breast Cancer, Breakthrough Award Level 4
This grant funds clinical trials in breast cancer research with high breakthrough potential, requiring consumer advocates and allowing single or dual principal investigators for FY26.
Funder: Dept. of the Army -- USAMRAA
Due Dates: June 12, 2026: Pre-Application (Preproposal) submission deadline (5:00 p.m. ET) | September 30, 2026: Full application submission deadline (11:59 p.m. ET) | October 5, 2026: End of application verification period (5:00 p.m. ET)
Funding Amounts: Up to $21,000,000 total for one award over a maximum of four years.
Summary: Supports large-scale, high-impact clinical trials addressing key challenges in breast cancer, requiring consumer advocate involvement and a focus on transformative clinical management or prevention.
Key Information: Clinical trial is required; team must include at least two breast cancer consumer advocates.
Description
This opportunity, offered by the Department of the Army's USAMRAA through the Breast Cancer Research Program (BCRP), Breakthrough Award Level 4, funds ambitious, large-scale clinical trials that have the potential to transform the prevention or clinical management of breast cancer. Research must address at least one of the BCRP's overarching challenges (e.g., prevention, risk determination, overdiagnosis, metastatic disease, or revolutionizing treatment) or provide a compelling justification for an alternative focus. The program emphasizes impact, innovation, and direct clinical relevance, and requires active integration of breast cancer consumer advocates in the research team.
Distinctive features include:
- Mandatory clinical trial component.
- Inclusion of at least two breast cancer consumer advocates as integral team members.
- Option for a single PI or a partnering PI structure (Initiating PI and Partnering PI).
- Intended for projects with the potential for major breakthroughs and high clinical impact.
